Back to mobile site

Oppenheimer Reiterates Outperform Rating on Eupraxia Pharmaceuticals (EPRX)

October 20, 2026 12:12 PM EDT Send to a Friend
Oppenheimer analyst Jay Olson reiterated an Outperform rating and $17.00 price target on Eupraxia Pharmaceuticals (NASDAQ: EPRX).The analyst comments "Detailed ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login